DrugPatentWatch Database Preview

Baricitinib - Generic Drug Details

« Back to Dashboard

What are the generic sources for baricitinib and what is the scope of baricitinib patent protection?

Baricitinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baricitinib has fifty-two patent family members in forty countries.

One supplier is listed for this compound.

Summary for baricitinib

International Patents:	52
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	80
Clinical Trials:	44
Patent Applications:	71
DailyMed Link:	baricitinib at DailyMed

Pharmacology for baricitinib

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Synonyms for baricitinib

(1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile

{1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile

1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile

1187594-09-7

2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE

3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-

3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-

3JW

AB0035958

ABP001023

AC-27404

AJ-121247

AK143352

AKOS022186127

AKOS025401933

AM81232

AMMD00005

AOB87724

AX8261519

Baricitinib (INCB28050 LY3009104)

Baricitinib (JAN/USAN/INN)

Baricitinib (LY3009104, INCB028050)

Baricitinib (LY3009104)

Baricitinib [USAN:INN]

baricitinib-ly3009104

BC600315

BCP04686

BCP0726000031

BCP9000380

BDBM50021656

C16H17N7O2S

CHEBI:95341

CHEMBL2105759

CS-0724

D10308

DB11817

DS-7641

DTXSID30152228

EX-A413

GTPL7792

HMS3651L17

HY-15315

INCB 028050

INCB 28050

INCB-028050

INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile

INCB028050

ISP4442I3Y

J-503551

KS-0000044L

LY 3009104

LY-3009104

LY3009104

MFCD21608464

MLS006011247

NCGC00345839-01

NCGC00345839-14

olumiant

Olumiant (TN)

PB27275

QCR-197

RL00725

S-7686

s2851

SB10845

SC-94301

SCHEMBL871150

SMR004703006

SW220096-1

UNII-ISP4442I3Y

XUZMWHLSFXCVMG-UHFFFAOYSA-N

Y0439

ZINC73069247

US Patents and Regulatory Information for baricitinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	Yes			Y	Y
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	Yes
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	Yes

International Patents for baricitinib

Country	Patent Number	Estimated Expiration
Peru	00992014
Ecuador	SP10010475
Mexico	2010010012

Supplementary Protection Certificates for baricitinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2288610	2017033	Norway		PRODUCT NAME: BARICITINIB OG FARMASOEYTISK; REG. NO/DATE: EU/1/16/1170 20170222
2288610	2017C/025	Belgium		PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610	C20170022 00232	Estonia		PRODUCT NAME: BARITSITINIIB;REG NO/DATE: EU/1/16/1170 15.02.2017